Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.
Corcept DAZALS Phase 2 Data Drives CORT Stock Move
The DAZALS study revealed that patients treated with 300 mg of dazucorilant daily exhibited improved overall survival rates.
ALS, or Lou Gehrig’s disease, is a progressive, fatal neurodegenerative disease that destroys motor neurons in the brain and spinal cord, causing voluntary muscle loss, paralysis, and respiratory failure.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
What’s Behind The Jump In Corcept Therapeutics Stock?